Purpose: To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma.
Introduction
The treatment of patients with advanced or metastatic pancreatic adenocarcinoma remains unsatisfactory. Although the effect of palliative chemotherapy on symptom control and prolongation of survival has been demonstrated, the effects are marginal. All agents tested adequately in phase II-trials do not produce objective response rates in excess of 10%-15% [1, 2] .
Methotrexate, if given prior to 5-FU increases the cellular pools of phosphoribosylpyrophosphates, leading to increased formation of fluorodeoxyuridine-monophosphate and fluorouraciltriphosphate, the two toxic metabolites of 5-FU [3] .
PALA (N-phosphonacetyl-L-asparate) is a specific inhibitor of aspartatetranscarbamylase and thereby inhibitis de novo synthesis of pyrimidines [4, 5] . When given at a dose of 250 mg/m 2 24 hours prior to 5-FU, the addition of PALA resulted in promising antitumor activity in colorectal cancer [6] . This phase II trial should evaluate the activity of a biochemical modulation of 5-FU by methotrexate and PALA in advanced pancreatic cancer.
Patients and methods
Patients have been entered by four university hospitals. Inclusion criteria: histologically documented pancreatic carcinoma, not amenable to surgical or radiotherapeutic procedures; no prior chemotherapy; measurable disease; age 18 to 75 years; ECOG-performance status 0-2; normal blood counts and ceratinine, bilirubin and transaminases less than two times upper limit; informend consent. The protocol was reviewed and approved by the responsible ethics committees. Patients with significant pleural effusions or ascites were not eligible.
Treatment protocol
Treatment protocol: PALA (US-Bioscience) 250 mg/m 2 15 minutes infusion day 1, methotrexate (200 mg/m 2 ) 30 minutes infusion immediately after PALA; 5-FU 600 mg/m 2 i.v. push 24 hours after PALA (day 2). Folinic acid 15 mg/m 2 orally every six hours for a total of eight doses starting 24 hours after methotrexate.
In case of protracted excretion of MTX folinic acid rescue was continued until MTX plasma levels were below 10" 7 mol/1. Cycles were repeated every two weeks.
In the absence of greater than grade 1 toxicity (WHO criteria), 5-FU was escalated in steps of 100 mg/m 2 , maximum dose of 5-FU allowed was 900 mg/m 2 /cycle.
Side effects were assessed every two weeks and rumor response every four to six weeks according to WHO guidelines. Treatment was continued until documented tumor progression or unacceptable toxicity.
Results
Thirty patients with advanced pancreatic carcinoma were entered. Twenty-six patients had measurable disease. Patient characteristics are summarized in Table 1 .
One patient achieved a partial response (3.9%). Additional nine patients had stable disease for more than two months. Median time to documented tumor progression was 91 days (95% confidence interval (95% CI) 43-146 days); median survival was 177 days (95% CI 121-237 days) and one year survival was 13.3% (4 of 30 patients).
Ten patients had dose escalations of 5-FU performed; six patients received 700 mg/m 2 , three patients 800 mg/ m 2 and one patient 900 mg/m 2 . The most prominent side effects were mucositis and diarrhea. Mucositis WHO grade 2 and 3 occurred in seven and two patients; diarrhea grades 2 and 3 in four and two patients, respectively. One instance of reversible WHO grade 3 nephrotoxicity related to methotrexate infusion occurred.
Discussion
The effect of chemotherapy in advanced pancreatic carcinoma is marginal. New agents, especially gemcitabine and taxotere, have shown some activity in this disease [7, 8] . However, 5-FU remains the most extensively studied drug. Folinic acid, which effectively increases 5-FU activity in colon cancer appears to be ineffective in pancreatic cancer [9] . Therefore, we attempted another way to increase the efficacy of 5-FU. Both, methotrexate and PALA, have been shown to be effective modulating agents in vivo [4, 5, 10 ]. An interval of 24 hours between MTX and 5-FU has been shown to be superior to a one-hour interval in a randomized trial in colon cancer [10] . Low doses of PALA (250 mg/m 2 ) effectively decrease pyrimindine biosynthesis with a maximum effect after 24 hours to 48 hours [4, 5] . The results of this trial indicate that the combination of PALA, methotrexate and 5-FU given in this dose and schedule appears to be ineffective. Several explanations are possible: a) pancreatic cancer cells might not respond to this biochemical modulation in vivo, b) the dose of PALA might have been to low to effectively inhibit pyrimidine de novo synthesis, c) the dose intensity of 5-FU might have been to low.
The identification of active agents and combination protocols for the treatment of patients with advanced pancreatic carcinoma remains of most importance.
